GlassScriptPhysician profile
Mia Schexnayder-Davis
NPI 1609254630
$9,505.70
in general payments reported to CMS, 2019-2025
20 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 88% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $734 · 2022: $2,125 · 2023: $3,466 · 2024: $2,072 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,569 · Education: $77.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,568.85 |
| Education | $77.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,271.64 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,215.34 | 2021-2025 | Invega, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $1,112.26 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,044.14 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $1,021.60 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,020.49 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Indivior INC. | $726.43 | 2021-2024 | Perseris, Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $658.65 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $444.94 | 2024-2025 | Auvelity |
| Lundbeck LLC | $197.76 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Boston Scientific Corporation | $143.05 | 2021-2022 | |
| Dexcom, INC. | $124.21 | 2021 | |
| Genzyme Corporation | $118.54 | 2023 | |
| Lilly USA, LLC | $103.30 | 2024 | Mounjaro |
| Ucb, INC. | $96.24 | 2023 | Fintepla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $64.65 | 2022-2025 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $56.39 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $45.10 | 2022-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $24.51 | 2021 | |
| Braeburn INC. | $16.46 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Schexnayder-Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.